NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results, Beats Expectations By $1.66 EPS

NuCana (NASDAQ:NCNA) posted its earnings results on Thursday. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($2.65) by $1.66, Zacks reports.

NuCana Price Performance

NASDAQ NCNA traded up $0.05 during mid-day trading on Thursday, hitting $1.48. The stock had a trading volume of 15,645 shares, compared to its average volume of 35,395. The firm’s 50 day moving average is $1.52 and its 200 day moving average is $1.87. NuCana has a twelve month low of $1.21 and a twelve month high of $7.22. The stock has a market capitalization of $6.16 million, a price-to-earnings ratio of -0.50 and a beta of 2.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, NuCana has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.